×

Celladon Corporation to Present at 11th Global Cardio Vascular Clinical Trial Forum

SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Janice Pogoda, Ph.D., Executive Director of Biostatistics at Celladon, has been selected to present guidance for future clinical trials of therapies for cardiac disease during the 11th Global Cardio Vascular Clinical Trial Forum (CVCT). The presentation will take place during Session 1: The Specific Framework of Cell and Gene Therapy Trials, on Saturday, December 6, 2014 from 11:30 a.m. – 3:00 p.m. EST in Washington D.C.

"We are honored that Janice has been selected to speak at the prestigious CVCT forum and believe it is a testament to our leadership in cardiovascular disease," said Krisztina Zsebo, Chief Executive Officer of Celladon. "Ongoing research and development is critical to ensure we are bringing the best therapies possible to patients and we are proud to support the efforts of CVCT."

The CVCT Forum brings together key decision makers, clinical trial specialists, methodologists, investigators, regulatory authorities and industry R&D experts to discuss trial design, conduct, interpretation, approval and implementation to support the development of next generation therapies and devices for cardiovascular disease.

About Celladon

Celladon is a clinical-stage biotechnology company applying its leadership position in the field of cardiovascular gene therapy to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target SERCA enzymes which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, vascular disease, diabetes and neurodegenerative diseases. MYDICAR, the Company's most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with advanced heart failure. Celladon has completed enrollment of a 250 patient Phase 2b clinical trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of MYDICAR versus placebo added to a maximal, optimized heart failure regimen in patients with New York Heart Association class III or IV symptoms of chronic heart failure due to systolic dysfunction. The Company has received Breakthrough Therapy designation from the FDA for this MYDICAR program and expects to report results from the Phase 2b clinical trial in April 2015. In addition, the Company conducts research and development on its mSCF gene therapy program for cardiac diseases. Celladon has also identified a number of potential first-in-class compounds addressing novel targets in diabetes and neurodegenerative diseases with its small molecule platform of SERCA2b modulators. For more information, please visit www.celladon.com.

Forward-Looking Statements –

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Celladon's plans to research, develop and commercialize product candidates, as well as expected timing for reporting results from clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Celladon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the process of conducting product development activities and clinical trials and obtaining regulatory approval to commercialize product candidates, our reliance on third parties, the need to raise additional funding when needed in order to conduct our business, and the degree of market acceptance of MYDICAR by physicians, patients, third-party payors and others in the medical community. These and other risks and uncertainties are described more fully in Celladon's filings with the Securities and Exchange Commission, including without limitation its Form 10-Q for the quarter ended September 30, 2014. All forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: For further information, please contact: Fredrik Wiklund Vice President, Corporate Development and Investor Relations +1- 858-432-7215 fwiklund@celladon.net

Source:Celladon Corporation